Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lobaplatin versus epirubicin TACE for unresectable hepatocellular carcinoma
ChiCTR1800016395Phase 4Recruiting
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Jun 2018
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in hepatocellular carcinoma (HCC) comparing Lobaplatin TACE with Epirubicin TACE (2 arms). Primary endpoint: Progression-free survival. Started Jun 2018; status: recruiting.
02
Drugs
lobaplatinepirubicin
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR1800016395.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800016395.